We read with interest the study by Koh et al., which continues the discussion on the safety and efficacy of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). The topic is very important as clinicians seek to optimize the few available choices in treating MDR- and XDR-TB patients.

Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

SPANEVELLO, ANTONIO;
2009-01-01

Abstract

We read with interest the study by Koh et al., which continues the discussion on the safety and efficacy of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). The topic is very important as clinicians seek to optimize the few available choices in treating MDR- and XDR-TB patients.
2009
http://jac.oxfordjournals.org/content/64/5/1119.1.long
MDR-TB, XDR-TB, adverse events
Sotgiu, G; Lange, C; Richardson, Md; Matteelli, A; Centis, R; Eker, B; Guenther, G; Spanevello, Antonio; Migliori, Gb
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/1759080
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact